These are exciting times to be in research and development. We are a leader, creating a new kind of enterprise: a next-generation BioPharma company. We honor and preserve what is best about our roots as a traditional pharmaceutical company while embracing what is best about leading-edge biotechnology companies.

Taking the best of biotech, we have a passion for innovative science, a focus on serious diseases with significant unmet medical need and a clear competitive advantage in biologics. We are creating a more entrepreneurial culture, one that values individual contributions while fostering collaborative and productive teamwork.

Taking the best of big pharma, we retain our ability to serve global markets in an efficient way; our expertise in process engineering, in clinical development and in integrating capabilities across multiple disease areas; and our traditional focus on advancements in chemistry that have led to truly innovative small molecules-based therapeutics.

As a next-generation BioPharma leader, our business will have three characteristics:

• A continued focus on an innovative portfolio
• A selectively integrated business model
• An unrelenting focus on continuous improvement